FibroGen, Inc. (NASDAQ:FGEN – Get Rating) – Equities research analysts at Jefferies Financial Group increased their Q3 2022 earnings per share estimates for shares of FibroGen in a research report issued to clients and investors on Tuesday, August 9th. Jefferies Financial Group analyst M. Yee now forecasts that the biopharmaceutical company will earn ($0.84) per share for the quarter, up from their prior estimate of ($0.98). The consensus estimate for FibroGen's current full-year earnings is ($3.24) per share. Jefferies Financial Group also issued estimates for FibroGen's Q4 2022 earnings at ($0.86) EPS, FY2022 earnings at ($3.18) EPS and FY2023 earnings at ($3.36) EPS.

Other equities research analysts have also issued reports about the stock. StockNews.com lowered shares of FibroGen from a "buy" rating to a "hold" rating in a research note on Wednesday. The Goldman Sachs Group reduced their price target on FibroGen from $9.00 to $8.00 and set a "sell" rating for the company in a research report on Tuesday, May 24th.

FibroGen Stock Up 3.1 %

FibroGen (NASDAQ:FGEN – Get Rating) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.94) by $0.16. The business had revenue of $29.81 million during the quarter, compared to the consensus estimate of $36.15 million. FibroGen had a negative return on equity of 100.51% and a negative net margin of 83.64%. FibroGen's quarterly revenue was up 22.3% on a year-over-year basis. During the same period last year, the company earned ($1.45) earnings per share.

Institutional Investors Weigh In On FibroGen

A number of large investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. grew its stake in FibroGen by 235.9% in the 4th quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company's stock valued at $52,630,000 after buying an additional 2,621,494 shares during the last quarter. Soleus Capital Management L.P. acquired a new stake in FibroGen during the 4th quarter worth approximately $21,862,000. Federated Hermes Inc. boosted its stake in FibroGen by 84.1% in the 1st quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company's stock valued at $28,799,000 after purchasing an additional 1,094,403 shares during the period. First Trust Advisors LP grew its holdings in FibroGen by 24.8% in the 4th quarter. First Trust Advisors LP now owns 5,317,613 shares of the biopharmaceutical company's stock valued at $74,978,000 after buying an additional 1,055,536 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in FibroGen by 333.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 972,901 shares of the biopharmaceutical company's stock worth $10,274,000 after buying an additional 748,230 shares during the period. Institutional investors own 77.35% of the company's stock.

FibroGen Company Profile

(Get Rating)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Featured Articles

• Get a free copy of the StockNews.com research report on FibroGen (FGEN)
• 2 Important Retail Stock Battles to Watch
• MarketBeat: Week in Review 8/8 – 8/12
• What Is WallStreetBets and What Stocks Are They Targeting?
• Institutions And Analysts Propel Jack In The Box Higher
• Can You Guess Which EV Stock Is Beating Tesla ?

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.